Literature DB >> 1830143

[Surgical treatment of right-sided infective endocarditis].

J J Pagbe1, T Mesana, A Goudard, D Blin, R Gulino, A Cornen, A Mouly-Bandini, J R Monties.   

Abstract

Between 1980 and 1989, 8 patients (5 men, 3 women; mean age 30 years) were operated upon in our department of right-sided infective endocarditis. Six patients were heroin addicts and among these 3 were HIV positive and 2 had confirmed AIDS. The most frequently encountered microorganisms (6 cases) were staphylococci. It was decided to operate because of persistent infection and haemodynamic deterioration. The infection involved the pulmonary valve in only 1 of the 8 patients. Surgery was performed during the acute phase in 5 patients and was conservative in 6 patients, consisting of excision of the vegetations or valvulectomy combined or not with valvuloplasty. A high mortality rate (3/8 cases) was observed only among patients operated upon in the acute phase. This may be due to the underlying immunodeficiency and poor haemodynamic state of these patients. Among survivors, the long-term results were excellent, with no recurrent endocarditis and no death, and with only one subsequent operation, 4 years after the first one, for residual tricuspic valve regurgitation. This study shows that patients with right-sided infective endocarditis should be operated upon outside the acute phase of the disease and as soon as complications appear, and that surgery should preferably be conservative.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1830143

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  1 in total

1.  Drug Use and Postoperative Mortality Following Valve Surgery for Infective Endocarditis: A Systematic Review and Meta-analysis.

Authors:  Ryan Hall; Michael Shaughnessy; Griffin Boll; Kenneth Warner; Helen W Boucher; Raveendhara R Bannuru; Alysse G Wurcel
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.